Stay updated on Preventing GvHD in Allo ApoGraft SCT - Clinical Trial
Sign up to get notified when there's something new on the Preventing GvHD in Allo ApoGraft SCT - Clinical Trial page.

Latest updates to the Preventing GvHD in Allo ApoGraft SCT - Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check41 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check55 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check62 days agoChange DetectedThe intervention type has been updated to 'Verified 2019-11 by Cellect Biotechnology' with the last known status as 'Recruiting', reflecting a revision from v2.13.3 to v2.14.0.SummaryDifference3%
- Check92 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.3%
Stay in the know with updates to Preventing GvHD in Allo ApoGraft SCT - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Preventing GvHD in Allo ApoGraft SCT - Clinical Trial page.